Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996–99
Open Access
- 1 April 2001
- journal article
- Published by Wiley in HIV Medicine
- Vol. 2 (2) , 84-88
- https://doi.org/10.1046/j.1468-1293.2001.00057.x
Abstract
1 Unité INSERM 330, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux and 2 Centre d'Information et de Soins de l'Immunodéficience Humaine, Centre Hospitalier Universitaire de Bordeaux, France Objective To estimate the incidence of serum hypertriglyceridaemia > 6 mm/L (HTG) and identify associated factors in the era of highly active antiretroviral therapy (HAART).Methods A prospective cohort, multirisk, both genders, of HIV‐infected patients was treated with several patterns of antiretrovirals. Cox's model was used to estimate the effect of explanatory variables documented at the first normal triglyceride measurement (< 2 mm/L) on the subsequent occurrence of HTG.Results Among 925 patients (27% treated with a protease inhibitor (PI) containing regimen and 48% treated with other HAART combinations) followed 25 months in median with a median triglyceridaemia of 1.1 mm/L at baseline, 70 experienced an HTG, 4.2 cases per 100 person years[95% confidence interval (CI)=2,2,3,3–5]. Univariate analysis retained the following as risk factors of HTG: male gender, homosexual transmission group, greater age, higher body weight, AIDS stage, ≥ 2 antiretrovirals including PI, higher triglyceride level and lower CD4+ cell count at baseline. In multivariate analysis, the risk of HTG remained associated with being male homosexual [hazard ratio (HR) = 1.68, P = 0.04], at the AIDS stage (HR = 1.84, P = 0.03), with increased triglyceride level (HR = 2.82 for 1 mm/L higher at baseline, P < 10−3), impaired CD4+ cell count (HR = 1.2 for 100 cells/μL lower, P = 0.02) and increased body weight (HR = 1.3 for 10 kg higher, P = 0.02).Conclusions Baseline triglyceride level and being overweight are risk factors of HTG, together with advanced HIV disease, but the contribution of HAART is not demonstrated.Keywords
This publication has 20 references indexed in Scilit:
- Serum Triglycerides, HIV Infection, and Highly Active Antiretroviral Therapy, Aquitaine Cohort, France, 1996 to 1998JAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Serum Triglycerides, HIV Infection, and Highly Active Antiretroviral Therapy, Aquitaine Cohort, France, 1996 to 1998JAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Acute pancreatitis in human immunodeficiency virus–infected patients: a reviewThe American Journal of Medicine, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Lipid Abnormalities Associated With Protease InhibitorsJournal of the Association of Nurses in AIDS Care, 1999
- Ritonavir, Triglycerides, and PancreatitisClinical Infectious Diseases, 1999
- Adsorption of C3 Alcohols, 1-Butanol, and Ethene on Platinized Platinum As Studied with FTIRS and DEMSLangmuir, 1997
- Metabolic Disturbances and Wasting in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1992
- Body fat distribution, plasma lipids, and lipoproteins.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988